Sign In
Section Navigation
Common TitleNEAT 022
Official Title Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)
Phase Phase IV
ClinicalTrials.gov NCT02098837
Treatments
Dolutegravir
Dolutegravir Tivicay

Dolutegravir

Tradename:TivicayOther Names:DTGClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories PharmacologySwitch/SimplificationAdverse Effects
Funding
Non-IndustrySt Stephens Aids Trust
References
  • Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503-14.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.